Vertex Pharmaceuticals (VRTX) - Analysts' Weekly Ratings Changes

Vertex Pharmaceuticals (VRTX) - Analysts' Weekly Ratings Changes


Several brokerages have updated their recommendations and price targets on shares of Vertex Pharmaceuticals in the last few weeks: 6/29/2016 - Vertex Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a "strong sell" rating to a "hold" rating. According to Zacks, "Vertex, which previously had a presence in the HCV market, is currently focused on cystic fibrosis treatments.



from Biotech News